Leadership Overview
Organon has 4 executives leading key functions including corporate strategy, human capital management, medical research operations, and international market expansion.
Focused on advancing global wellness, Organon delivers essential therapies for women while maintaining a diverse portfolio of over 70 medicines across 140 markets to ensure community health.
Focused on advancing global wellness, Organon delivers essential therapies for women while maintaining a diverse portfolio of over 70 medicines across 140 markets to ensure community health.
Leadership Roles at Organon
Mazen Altaruti - President, Emerging Markets (Japan)
Mazen Altaruti, the President, Emerging Markets (Japan) at Organon, directs commercial operations and market access strategies within the Japanese pharmaceutical landscape. Altaruti oversees the distribution of reproductive health and cardiovascular medicines, tailoring the company's global portfolio to meet specific regional healthcare requirements. The President, Emerging Markets (Japan) manages local partnerships to ensure that patients receive consistent access to affordable treatments. Mazen Altaruti drives growth initiatives by identifying unique market opportunities and navigating complex regulatory environments. By aligning regional activities with the overarching corporate mission, the President, Emerging Markets (Japan) strengthens the company's presence in key Asian territories. Altaruti coordinates with global leadership to implement scalable business models that enhance community well-being. This role involves constant monitoring of market trends to maintain a competitive edge, ensuring that the organization effectively addresses the health needs of women and families throughout the region.
Jo Snyder - Chief of Staff
Jo Snyder, the Chief of Staff at Organon, coordinates executive workflows to ensure alignment with the global mission of improving women's health. Snyder manages cross-functional communication channels, facilitating rapid decision-making processes across the leadership team. By streamlining internal operations, the Chief of Staff enables the organization to focus resources on the development of reproductive health and cardiovascular therapies. Jo Snyder monitors key performance indicators to track progress against long-term corporate objectives. This role involves bridging gaps between departments to maintain operational efficiency across the 140 markets served by the company. Through rigorous oversight of strategic initiatives, the Chief of Staff supports the broader goal of providing affordable treatments to families worldwide. Snyder maintains a constant focus on organizational agility, ensuring that internal structures remain responsive to the evolving needs of the pharmaceutical industry and the patients relying on these essential medical solutions.
Aaron Falcione - Chief Human Resources Officer
Aaron Falcione, the Chief Human Resources Officer at Organon, directs the global talent strategy to support the company's commitment to women's health. Falcione architects comprehensive programs for employee development, ensuring the workforce possesses the expertise required to manage a portfolio of over 70 medicines. The Chief Human Resources Officer oversees organizational culture initiatives, fostering an environment that prioritizes innovation and community well-being. Aaron Falcione aligns human capital investments with the company's expansion goals across diverse international markets. By implementing robust recruitment and retention frameworks, the Chief Human Resources Officer secures the specialized talent necessary for advancing complex medical research. Falcione collaborates with other executive leaders to integrate human resources policies into the broader business model, driving operational excellence. This leadership role ensures that the global team remains motivated and equipped to deliver high-quality healthcare solutions to patients in every region of operation.

Anouk Lindley - Head of Strategic Operations, Medical Affairs & Outcomes Research Chief of Staff
Anouk Lindley, the Head of Strategic Operations, Medical Affairs & Outcomes Research Chief of Staff at Organon, manages the integration of clinical data into the company's strategic framework. Lindley oversees the operational execution of medical affairs, ensuring that research outcomes directly inform the development of therapies for autoimmune disorders and reproductive health. The Head of Strategic Operations, Medical Affairs & Outcomes Research Chief of Staff coordinates with research teams to validate the efficacy of the diverse product portfolio. Anouk Lindley drives the translation of complex medical findings into actionable business strategies that enhance patient access across 140 markets. By optimizing research workflows, the Head of Strategic Operations, Medical Affairs & Outcomes Research Chief of Staff ensures that clinical evidence supports the company's mission of improving health throughout women's lives. Lindley maintains rigorous standards for data integrity, facilitating the delivery of essential medicines to global communities through evidence-based decision-making processes.
Explore Leadership Teams in Manufacturing
Genentech, Inc. specializes in developing prescription medicines for the treatment of multiple sclerosis (MS), specifically targeting relapsing forms and primary progressive MS in adults. Their primary products, OCREVUS® (ocrelizumab) and OCREVUS ZUNOVO® (ocrelizumab & hyaluronidase-ocsq), offer both intravenous and subcutaneous administration options. The company aims to provide effective treatment solutions while also offering support services, financial assistance, and resources for patients living with MS. Genentech is committed to improving the quality of life for individuals affected by MS through innovative therapies and comprehensive care.
Company Leadership AM
MM
BR
NF
Founded in 2005, Headquartered in Tokyo, Daiichi Sankyo is a global pharmaceutical company that develops and provides innovative new and generic medicines, as well as advanced drug discovery and delivery methods, serving patients in over 30 countries.
Company Leadership
KM
Cipla Limited is a global pharmaceutical company based in Mumbai, India, with operations in India, the United States, South Africa, and other international markets. Through its Pharmaceuticals and New Ventures segments, the company develops, manufactures, markets, and distributes a broad range of generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and finished formulations. Its products address multiple therapeutic areas, including cardiovascular disease, pulmonary and kidney conditions, neurological and psychiatric disorders, HIV/AIDS, respiratory and asthma care, oncology, diabetes and metabolic disorders, infectious diseases, critical care, women’s health, ophthalmology, and child health. In addition to its core pharmaceutical portfolio, Cipla is active in consumer healthcare, biosimilars, and specialty medicine businesses. Founded in 1935, Cipla has grown into a major global healthcare player.
Company Leadership MF
PJ
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is headquartered in South Plainfield, New Jersey.
Company Leadership LB
DM
